Navigation Links
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Date:2/4/2008

HORSHAM, Pa., Feb. 4 /PRNewswire/ -- Centocor, Inc. announced today that the Biologics License Application (BLA) for ustekinumab (CNTO 1275) has been accepted for review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic moderate to severe plaque psoriasis. Ustekinumab is a new, human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), naturally occurring proteins that are important in regulating immune responses and that are thought to be associated with some immune-mediated inflammatory disorders, including psoriasis.

"We are pleased by the FDA's acceptance of our Biologics License Application for review of ustekinumab," stated Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "Ustekinumab has yielded promising efficacy and safety results in Phase 3 clinical trials, and we look forward to working closely with the FDA during their ongoing review of this potential new treatment for psoriasis."

Centocor, Inc. announced that it had submitted the BLA for ustekinumab in December 2007 based on its comprehensive development program including data from two large Phase 3 multicenter, randomized, double-blind, placebo- controlled trials involving nearly 2,000 patients that evaluated the safety and efficacy of ustekinumab in the treatment of moderate to severe plaque-type psoriasis. The primary endpoint of both studies was the proportion of patients who achieved at least a 75 percent reduction in psoriasis as measured by the Psoriasis Area and Severity Index (PASI 75). Acceptance of the BLA filing does not mean that a license has been issued for this product nor does it represent any evaluation of the adequacy of the data submitted in the BLA. In December 2007 the Marketing Authorization Application (MAA) for ustekinumab was submitted in Europe and is currently under review by the European Medicines Agency (
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... SAN DIEGO , Feb. 16 BioMed Realty ... of an amendment to its lease with Ironwood Pharmaceuticals, Inc. (Nasdaq: ... in Cambridge, Massachusetts .  Ironwood has agreed to lease an ... its existing premises located in the heart of the Kendall Square ...
... , SAN FRANCISCO , Feb. 16 ... showcase innovative new initiatives at Informex this week, highlighting the ... to the global chemicals industry. , At Informex 2010, ... between seven leading universities, the private sector and the Scottish ...
... PLEASANTON, Calif. , Feb. 16 ... proprietary chemistry for nucleic acid testing applications that are relevant ... for the "Most Promising Company" award at the Personalized Medicine ... The PMWC 2010 was created to examine the emerging field ...
Cached Biology Technology:BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 2BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 3BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts 4Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 2Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 3Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 4QuantaLife, Inc. Unanimously Selected as the 'Most Promising Company' at the Personalized Medicine World Conference 2010 2QuantaLife, Inc. Unanimously Selected as the 'Most Promising Company' at the Personalized Medicine World Conference 2010 3QuantaLife, Inc. Unanimously Selected as the 'Most Promising Company' at the Personalized Medicine World Conference 2010 4
(Date:4/15/2014)... pairs, researchers from the Bloomberg School of Public ... reuptake inhibitors (SSRIs), a frequently prescribed treatment for ... autism spectrum disorder (ASD) and developmental delays (DD) ... edition of Pediatrics , analyzed data from ... population-based controls, where a uniform protocol was implemented ...
(Date:4/15/2014)... who study the deadliest infectious diseases recognized the contributions ... at the University of Texas Medical Branch, with a ... on Filoviruses. The filoviruses include Ebola and Marburg viruses ... people infected. The current outbreak of Ebola virus raging ... so far. , "This award represents the culmination ...
(Date:4/15/2014)... form could help reduce side effects by targeting the ... have developed nanoparticles that deliver one or two chemotherapy ... particles that can carry any more than that in ... a new way to build such nanoparticles, making it ... In a paper published in the Journal of ...
Breaking Biology News(10 mins):Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3
... held its breath when the tanker Jessica, loaded with 150,000 ... in the heart of one of the most precious, famous ... At risk were vast numbers of unique species of flora ... to his landmark theory of evolution by natural selection. ...
... policy-makers, business leaders and environmentalists are joining forces to ... taking part in an influential new forum at the ... February 22, the Nitrous Oxide Focus Group will engage ... Marks & Spencer, British Sugar, Defra, the Country Land ...
... , Imagine a gigantic, inflatable, sausage-like bag capable of ... equivalent of 2.2 days of current global emissions. Now try ... radius and several kilometres long, resting benignly on the seabed ... first blush, this might appear like science fiction, but its ...
Cached Biology News:First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4Nitrous oxide: definitely no laughing matter 2Into the abyss: Deep-sixing carbon 2
... coli containing a clone of the human Topoisomerase ... II alters the topological state of nucleic acids ... transient break which generates a separate DNA helix ... DNA passage mechanism, the enzyme can relax negatively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: